BNET Industries

Adeza

is in the Health Care Industry

Last Fiscal Year Sales:$37.4M
  • Private
  • US
Dow Jones Description

Adeza is a medical technology company located in Sunnyvale, California. Adeza's products are recognized worldwide through both direct sales and distribution in over 20 countries. Adeza's product focus is on proprietary tests and services for the diagnosis of pregnancy-related and female reproductive disorders including premature birth and infertility. In the U.S., preterm birth is the leading cause of perinatal mortality and morbidity with healthcare costs exceeding $18.1 billion annually. Adeza received an expedited premarket approval from the U.S. Food and Drug Administration (FDA) to market the proprietary FullTerm , The Fetal Fibronectin Test. FullTerm , The Fetal Fibronectin Test detects a protein found in pregnant women and is used as an aid in the assessment of the risk of premature birth from 22 to 35 weeks of pregnancy. The FullTerm , Fetal Fibronectin Test has demonstrated effectiveness in 125+ published peer-reviewed studies and is available on Adeza's TLiIQ System. Adeza...

President and Chief Executive Officer
Emory V Anderson
Number of Employees 100
Contact Information

1240 Elko Dr

Sunnyvale, California 94089

adeza.com

1 408 745 0975

NAICS Code Surgical and Medical Instrument Manufacturing: 339112

News & Analysis

adeza - All News and Analysis

  • Cytyc Acquires Adeza Biomedical Corporation

    - 2007-04-03

    MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC) today announced that its wholly-owned subsidiary, Augusta Medical Corporation, merged with and into Adeza Biomedical Corporation (Nasdaq: ADZA), with Adeza continuing as the surviving corporation and a wholly-owned subsidiary of Cytyc. The merger of Augusta and Adeza was consummated effective as of 10:36...

    Tags: Adeza

  • Cytyc Completes Cash Tender Offer for Adeza Biomedical Corporation

    - 2007-04-02

    MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC) today announced the completion of the tender offer by its direct wholly-owned subsidiary, Augusta Medical Corporation, for all outstanding shares of Adeza Biomedical Corporation (Nasdaq: ADZA) at a price of $24.00 per share in cash. The subsequent offering period expired at 12:00...

    Tags: Adeza

  • Cytyc Acquires over 92 Percent of Adeza Shares in Tender Offer

    - 2007-03-22

    Remaining Shares to be Paid for Promptly upon Tender MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC) today announced that its wholly-owned subsidiary, Augusta Medical Corporation, has now purchased over 92 percent of the outstanding shares of common stock of Adeza Biomedical Corporation (Nasdaq: ADZA). Augusta had previously purchased approximately...

    Tags: Adeza

  • Cytyc Corporation Accepts Shares of Adeza Biomedical Corporation in Tender Offer and Commences Subsequent Offering Period

    - 2007-03-19

    MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC) today announced the expiration of the initial offering period of the tender offer by its wholly-owned subsidiary Augusta Medical Corporation ("Augusta") for all outstanding shares of common stock of Adeza Biomedical Coporation (Nasdaq: ADZA). The initial offering period expired, as scheduled, at 12:00...

    Tags: Cytyc Corp.

  • Cytyc Corporation Announces Expiration of Antitrust Waiting Period for Adeza Biomedical Corporation Tender Offer

    - 2007-03-14

    MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), expired at 11:59 p.m., New York City time, on March 13, 2007, in connection with the previously announced proposed acquisition by Cytyc of Adeza...

    Tags: antitrust, Cytyc Corp.

  • Adeza to Be Acquired by Cytyc for $24 Per Share

    - 2007-02-12

    Purchase Price of Approximately $450 Million SUNNYVALE, Calif. -- Adeza (NASDAQ:ADZA) today announced the signing of a definitive agreement to be acquired by Cytyc Corporation (NASDAQ:CYTC), a leading provider of surgical and diagnostic products targeting women's health and cancer diagnostics, for $24 per share, which is a purchase price...

    Tags: Adeza

  • Cytyc to Acquire Adeza Biomedical Corporation

    - 2007-02-12

    Expands Women's Healthcare Diagnostic Products Net Purchase Price of $356 Million MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC), a leading provider of surgical and diagnostic products targeting women's health and cancer diagnostics, today announced that it has entered into an agreement to acquire Adeza Biomedical Corporation (Nasdaq: ADZA)...

    Tags: Adeza

  • Adeza Biomedical Corporation to be Acquired by Cytyc.

    - 2007-02-12

    M2 PRESSWIRE-12 February 2007-Headline Maker: Adeza Biomedical Corporation to be Acquired by CytycC1994-2007 M2 COMMUNICATIONS LTD RDATE:12022007 Adeza (NASDAQ:ADZA) designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare using its proprietary technologies to predict...

    Tags: Adeza

  • Adeza to Be Acquired by Cytyc.

    - 2007-02-12

    M2 PRESSWIRE-12 February 2007-Headline Maker: Adeza to Be Acquired by CytycC1994-2007 M2 COMMUNICATIONS LTD RDATE:12022007 Adeza (NASDAQ:ADZA) designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare using its proprietary technologies to predict preterm...

    Tags: Adeza

  • Adeza Receives Orphan Drug Designation for Gestiva

    - 2007-01-31

    SUNNYVALE, Calif. -- Adeza (NASDAQ:ADZA) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration FDA has granted Orphan Drug designation covering Gestiva[TM], the company's therapeutic candidate for the prevention of preterm birth in women with a history of preterm delivery. If Gestiva is...

    Tags: Adeza

Decision Makers

Name (plus bio) Position
Emory V Anderson President and Chief Executive Officer
Mark D. Fischer-Colbrie Vice President of Finance and Administration and Chief Financial Officer
Durlin E Hickok Vice President of Medical Affairs
Marian E. Sacco Vice President of Sales and Marketing
Robert O. Hussa Vice President of Research and Development
Craig C. Taylor Director
Kathleen D. Laporte Director
Michael P Downey Director

Board of Directors

Name (plus bio) Position
Andrew Senyei Chairman of the Board

Organization Position Status
Adeza President and Chief Executive Officer Current

Mark D. Fischer-Colbrie has been our Vice President of Finance and Administration and Chief Financial Officer since February 2001. From March 1992 to January 2001, Mr. Fischer-Colbrie served as Vice President, Finance and Administration and Chief Financial Officer for KeraVision, Inc., a company that filed for bankruptcy under federal bankruptcy laws in March 2001. He also held several financial positions at Maxtor Corporation from April 1986 through February 1992, including Vice President of Finance and Corporate Controller.

Organization Position Status
Adeza Vice President of Finance and Administration and Chief Financial Officer Current

Organization Position Status
Adeza Vice President of Medical Affairs Current
Fullterm Vice President, Medical Affairs Current
Virginia Mason Medical Center Chief Former
Omnia Inc. Vice President Former
Omnia Inc. Medical Director Former
University of Washington Assistant Professor Former

Marian E. Sacco has been our Vice President of Sales and Marketing since September 1997. From 1996 to 1997, Ms. Sacco was the Vice President of Marketing at Behring Diagnostics. Previously, Ms. Sacco was the Director of Worldwide Oncology Business and Worldwide Marketing Manager for CBA Corning/ Chiron Diagnostics from 1991 to 1996, and was the US Sales and Marketing Manager for Centocor Diagnostics from 1987 to 1991.

Organization Position Status
Adeza Vice President of Sales and Marketing Current

Dr. Hussa joined Adeza Biomedical in May 1993 as the Vice President, Research and Development. From January 1990 to his hire with Adeza, Dr. Hussa was the Vice President of Imaging and Therapeutics Research and Development at Hybritech, Inc., a medical device and therapeutics company, where he developed in vitro diagnostic tests in areas of reproductive endocrinology, cardiovascular disease and cancer. He also held the position of Director of Assay Development at Hybritech, from June 1986 to December 1989. For the 18 years preceding his employment with Hybritech, Dr. Hussa was a Professor of Gynecology & Obstetrics and Biochemistry at the Medical College of Wisconsin. He has published more than 80 articles and book chapters, and has edited and authored three books.

Organization Position Status
Adeza Biomedical Corporation Vice President, Research and Development Current
Adeza Vice President of Research and Development Current
Fullterm Vice President, Research and Development Current
Hybritech, Inc. Vice President of Imaging Former
Hybritech Director of Assay Development Former
Medical College of Wisconsin Professor Former
Hybritech Professor Former

Andrew E. Senyei, MD, Chairman of the Board, has served as one of our directors since 1987. Dr. Senyei has been a Managing Director and a General Partner of Enterprise Partners, a venture capital firm, since 1987. Dr. Senyei was a founder of Molecular Biosystems and, prior to joining Enterprise Partners, was a practicing clinician and Adjunct Associate Professor of Obstetrics, Gynecology and Pediatrics at the University of California at Irvine. He serves on the boards of directors of numerous private healthcare companies.

Organization Position Status
Adeza Chairman of the Board Current

Organization Position Status
Alloy Ventures, Inc. Partner Current
Fortebio, Inc Board Director for Fortebio and Partner at Alloy Ventures Current
Galileo Pharmaceuticals, Inc. General Partner, Alloy Venture Current
Fullterm Principal Accountant Fees and Services Current
Picoliter Current
Solexa, Inc. Chairman of the Board Current
Optimedica Corp. Director Current
Fullterm Director Current
Pharmacyclics, Inc. Board of Directors Current
Labcyte, Inc. Director Current
BioSpace.com, Inc. Board of Directors Current
Zyomyx Inc Board of Directors Current
Adeza Director Current
K2 Optronics, Inc. Board Member Current
ForteBio Board Member Current
Adeza Biomedical Corporation Director Current
Alloy Ventures, Inc. Owner Current
Asset Management Company Former
Solexa, Inc. Board of Directors Former
Stanford University MBA Former
Brown University MS In Physics Former
Stanford Company MBA Former
Stanford University BS Former
Brown University BS Former

Kathleen D. LaPorte , age 45, has served as a member of the Board of Directors since April 1997. Since July 2005, Ms. LaPorte has been a managing director of New Leaf Venture Partners, a life science venture capital firm. From 1994 to June 2005, Ms. LaPorte was a General Partner at the Sprout Group, a venture capital firm affiliated with Credit Suisse First Boston. Ms. LaPorte currently serves on the board of directors of Affymax, Inc., a publicly traded biopharmaceutical company, eHealth, Inc., a publicly traded healthcare technology company, ISTA Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, Adeza Biomedical Corporation, a publicly traded medical device company, and several privately-held companies. Ms. LaPorte holds a B.S. in Biology from Yale University and an M.B.A. from the Stanford University Graduate School of Business.

Organization Position Status
New Leaf Venture Partners Managing Director Current
Sprout Group Representative Current
Healthcarereps.Com Current
Adeza Director Current
Ardea Biosciences, Inc.De Board of Directors Current
Insureco Marketing LLC Director Current
TransOral Pharmaceuticals, Inc. Board Member Current
Prometheus Laboratories, Inc. Board of Directors Current
Fullterm Director Current
Cellgate, Inc Board of Directors Current
ISTA Pharmaceuticals, Inc. Board of Directors Current
Affymax, Inc. Board of Directors Current
Adeza Biomedical Corporation Board of Directors Current
Western Association of Venture Capitalists Past President Former
New Leaf Venture Partners Founder Former
Credit Suisse General Partner Former
Asset Management Company Principal Former
Western Association of Venture Capitalists Member of the Board Current
Stanford University Mba Former
Yale University BS Degree Former
Adeza Biomedical Corporation member Former

Organization Position Status
Adeza Director Current